Retail Traders Bet Big on Sellas Life Sciences Stock Surge

• Sellas Life Sciences is drawing significant attention from retail traders as the biotech company’s stock soars 15% on investor enthusiasm around its REGAL Phase 3 clinical trial catalyst.
• The rally reflects growing retail interest in the company’s pipeline and upcoming trial results.
• Traders are closely watching for potential positive data that could further drive the stock higher.
• The surge highlights retail investors’ appetite for biotech plays with near-term catalysts.

AI-generated briefing — triage, not the story; every claim links out to the coverage below.